zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2024-21-3-10zdor-2766Research ArticleЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНА И БИОЛОГИЯEXPERIMENTAL MEDICINE AND BIOLOGYОсобенности экспрессии маркеров ALDH1A1, CD271, CD133 и ISLR в эндометриоидной аденокарциноме тела матки при различных исходах заболеванияThe specificities of markers ALDH1A1, CD271, CD133 and ISLR expression in endometrioid adenocarcinoma of the uterine corpus at different disease outcomesЗиновкинД. А.ZinovkinD. A.

Зиновкин Дмитрий Александрович, к.б.н., доцент, доцент кафедры патологической анатомии, 

Гомель

Dmitry A. Zinovkin, Candidate of Biological Sciences, Associate Professor, Associate Professor at the Department of Pathology,

Gomel

zinovkin_da@gsmu.byЗятиковР. В.ZyatikovR. V.

Зятиков Роман Викторович, врач-патологоанатом отделения обшей патологии, 

Гомель

Roman V. Zyatikov, Pathologist at the General Pathology Department,

Gomel

zinych007@yandex.ruТетерскаяЮ. И.TeterskayaJ. I.

Тетерская Юлия Ивановна, врач-хирург,

Гомель

Julia I. Teterskaya, Surgeon, 

Gomel

yuliamuchina@rambler.ruУО «Гомельский государственный медицинский университет»Gomel State Medical UniversityГУЗ «Гомельское областное клиническое патологоанатомическое бюро»Gomel Regional Clinical Pathology BureauООО «ОМНИА Клиник»OMNIA Clinic (ltd)2024260720242137580Copyright © Зиновкин Д.А., Зятиков Р.В., Тетерская Ю.И., 20242024Зиновкин Д.А., Зятиков Р.В., Тетерская Ю.И.Zinovkin D.A., Zyatikov R.V., Teterskaya J.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/2766Цель исследования

Цель исследования. Выявить особенности экспрессии маркеров ALDH1A1, CD133, CD271 и ISLR в эндометриоидной аденокарциноме тела матки при благоприятном и неблагоприятном вариантах течения заболевания.

Материалы и методы

Материалы и методы. В исследовании использовался гистологический архивный материал 188 случаев эндометриоидной аденокарциномы тела матки. Все случаи были разделены на две группы в соответствии с исходом заболевания. В группу с благоприятным исходом вошло 148 случаев без прогрессии опухоли, в группу с неблагоприятным исходом — 40 пациенток, имевших прогрессирование заболевание за время наблюдения. Экспрессия ALDH1A1, CD271, CD133 и ISLR оценивалась как процент позитивных клеток к общему числу клеток в поле зрения. Сравнение групп проводилось с использованием теста Манна – Уитни.

Результаты

Результаты. Отмечались статистически значимые различия между группами (р < 0,05) в экспрессии ALDH1A1, CD271, CD133 и ISLR.

Заключение

Заключение. Экспрессия маркеров ALDH1A1, CD133 ISLR в группах с различным исходом заболевания может указывать на их предикторную роль в прогнозе эндометриоидной аленокарциномы тела матки.

Objective

Objective. To identify the expression patterns of ALDH1A1, CD133, CD271 and ISLR in endometrioid adenocarcinoma of the uterine corpus at different outcomes.

Materials and methods

Materials and methods. Histological archival material of 188 cases of endometrioid adenocarcinoma of the uterine corpus were used in the study. All cases were divided into 2 groups according to the outcome of the disease. The group with favourable outcome included 148 cases without tumour progression. The group with unfavourable outcome included 40 patients who had disease progression during follow-up. ALDH1A1, CD271, CD133 and ISLR expression was evaluated as the percentage of positive cells to the total number of cells in the field of view. Comparison of groups was performed using the Mann-Whitney test.

Results

Results. There were statistically significant differences between groups (p<0.05) in ALDH1A1, CD271, CD133 and ISLR expression. Conclusion. Expression of ALDH1A1, CD133 ISLR markers in groups with different disease outcome may indicate their predictive role in the prognosis of endometrioid adenocarcinoma of the uterine corpus. Keywords: endometrioid adenocarcinoma, ALDH1A1, CD271, CD133, ISLR> ˂ 0.05) in ALDH1A1, CD271, CD133 and ISLR expression.

Conclusion

Conclusion. Expression of ALDH1A1, CD133 ISLR markers in groups with different disease outcome may indicate their predictive role in the prognosis of endometrioid adenocarcinoma of the uterine corpus.

эндометриоидная аденокарциномаALDH1A1CD271CD133ISLRendometrioid adenocarcinomaALDH1A1CD271CD133ISLRReferencesSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021 Feb 4;71(3):209-249. DOI: https://doi.org/10.3322/caac.21660Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021 Feb 4;71(3):209-249. DOI: https://doi.org/10.3322/caac.21660Watkins JC, Downing MJ, Crous-Bou M, Busch EL, Chen MM, De Vivo I, et al. Endometrial tumor classification by histomorphology and biomarkers in the nurses’ Health Study. Journal of Cancer Epidemiology. 2021 Mar 12;2021:1-9. DOI: https://doi.org/10.1155/2021/8884364Watkins JC, Downing MJ, Crous-Bou M, Busch EL, Chen MM, De Vivo I, et al. Endometrial tumor classification by histomorphology and biomarkers in the nurses’ Health Study. Journal of Cancer Epidemiology. 2021 Mar 12;2021:1-9. DOI: https://doi.org/10.1155/2021/8884364Xia Y, Wang S, Sun Y, Wang W, Chang S, Zhang Z, et al. FZD5 induces chemoresistance through ALDH1A1 in ovarian cancer. 2024 Jan 29; DOI: https://doi.org/10.21203/rs.3.rs-3875162/v1Xia Y, Wang S, Sun Y, Wang W, Chang S, Zhang Z, et al. FZD5 induces chemoresistance through ALDH1A1 in ovarian cancer. 2024 Jan 29; DOI: https://doi.org/10.21203/rs.3.rs-3875162/v1DeLeo AB. Targeting cancer stem cells with ALDH1A1-based immunotherapy. OncoImmunology. 2012 May;1(3):385-387. DOI: https://doi.org/10.4161/onci.18826DeLeo AB. Targeting cancer stem cells with ALDH1A1-based immunotherapy. OncoImmunology. 2012 May;1(3):385-387. DOI: https://doi.org/10.4161/onci.18826Vidal A, Redmer T. Decoding the role of CD271 in melanoma. Cancers. 2020 Aug 31;12(9):2460. DOI: https://doi.org/10.3390/cancers12092460Vidal A, Redmer T. Decoding the role of CD271 in melanoma. Cancers. 2020 Aug 31;12(9):2460. DOI: https://doi.org/10.3390/cancers12092460Shen W. Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271. Cancer Biology & Medicine. 2019 Aug 1;16(3):498-513. DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0073Shen W. Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271. Cancer Biology & Medicine. 2019 Aug 1;16(3):498-513. DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0073Takahashi M, Kobayashi H, Mizutani Y, Hara A, Iida T, Miyai Y, et al. Roles of the mesenchymal stromal/stem cell marker Meflin/ISLR in cancer fibrosis. Frontiers in Cell and Developmental Biology. 2021 Oct 5;9. DOI: https://doi.org/10.3389/fcell.2021.749924Takahashi M, Kobayashi H, Mizutani Y, Hara A, Iida T, Miyai Y, et al. Roles of the mesenchymal stromal/stem cell marker Meflin/ISLR in cancer fibrosis. Frontiers in Cell and Developmental Biology. 2021 Oct 5;9. DOI: https://doi.org/10.3389/fcell.2021.749924Li S, Zhao W, Sun M. An analysis regarding the association between the ISLR gene and gastric carcinogenesis. Frontiers in Genetics. 2020 Jun 16;11. DOI: https://doi.org/10.3389/fgene.2020.00620Li S, Zhao W, Sun M. An analysis regarding the association between the ISLR gene and gastric carcinogenesis. Frontiers in Genetics. 2020 Jun 16;11. DOI: https://doi.org/10.3389/fgene.2020.00620Yondem E, Pesen-Okvur D. Cancer cell-derived extracellular matrix promotes differentiation of fibroblasts into cancer-associated fibroblasts. BioRxiv. 2024 Apr 20. DOI: https://doi.org/10.1101/2024.04.15.589578Yondem E, Pesen-Okvur D. Cancer cell-derived extracellular matrix promotes differentiation of fibroblasts into cancer-associated fibroblasts. BioRxiv. 2024 Apr 20. DOI: https://doi.org/10.1101/2024.04.15.589578Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clinical and Translational Medicine. 2018 July 09. DOI: https://doi.org/10.1186/s40169-018-0198-1Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clinical and Translational Medicine. 2018 July 09. DOI: https://doi.org/10.1186/s40169-018-0198-1

The authors declare that there are no conflicts of interest present.